Pharming announces extension of their license agreement for the commercialisation of Ruconest

17-Aug-2011 - Netherlands

Biotech company Pharming Group NV announced that they have agreed an extension of their existing agreement with Swedish Orphan Biovitrum to include new territories in the Balkans, North Africa and the Middle East for the commercialization of Ruconest® (recombinant human C1 inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).

In addition, SOBI has placed a significant additional order for vials of Ruconest®. The shipment forms part of SOBI's preparation for the continued roll-out and intensified marketing of Ruconest® across Europe. SOBI will over a period of 1 year pay €1.5 million to Pharming for these additional shipments under this order. Under the terms of the distribution partnership, SOBI buys finished product from Pharming for a transfer price that includes a sales related tiered royalty component.

Sijmen de Vries, CEO of Pharming, said "We are delighted to expand our current commercialization deal with SOBI. This is another significant step towards making Ruconest more widely available. With this extension, patients in all EC territories, the Balkans, North Africa and the Middle East will soon be able to benefit from the efficacy and safety that Ruconest offers as the only recombinant enzyme replacement therapy for HAE".

 

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances